hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
On September 11, 2019, Chief Justice of Ontario George Strathy said that the "cuts to Legal Aid Ontario will force many people to self-represent...What we judges can say is that reducing legal representation for the most vulnerable members of society does not save money. It increases trial times, places greater demands on public services, and ultimately delays and increases the cost of legal proceedings for everyone."
=== Infectious factors === Nursing mothers diagnosed with yeast, bacterial, viral infections or dermatitis are susceptible to nipple pain. A type of yeast infection called candidiasis caused by a type of fungus called Candida will lead to itching, erythema of the nipple and areola, burning and stabbing nipple pain. It happens when the infant's mouth is infected by a Candida species called Candida albicans, the child may transmit the yeast to the mother's nipple during breastfeeding. Bacterial infection by Staphylococcus aureus (S.aureus) will give rise to mastitis which refers to an inflammation of the mammary gland. About half of the breastfeeding mothers reporting nipple ache were infected with S.aureus. They usually experienced a sudden onset and systemic symptoms including nipple pain, fever, flu-like symptoms, myalgia and fatigue. The risk of infections increases with an inhibition of mammary gland drainage. Viral infection with Herpes simplex virus (HSV) causes nipple ulceration, soreness and pain. Infants feeding on an HSV infected nipple can develop a life-threatening complication affecting the brain called encephalitis. Breastfeeding women with dermatitis problems, including psoriasis and eczema at the nipple, suffer from erythema, scaling lesion and pain. Nursing mothers with psoriasis may develop Koebner phenomenon upon further nipple abrasion by infants in prolonged breastfeeding. Eczema at the nipple can be caused by direct chemical contact or allergic condition. It affects the areola and sometimes extends to the breast.
== Function == Nicotinamide phosphoribosyltransferase (iNAMPT) catalyzes the condensation of phosphoribosyl pyrophosphate with nicotinamide (NAM) to yield nicotinamide mononucleotide (NMN) and pyrophosphate (PPi). This is the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). This reaction allows a salvage pathway, in which NAM is recycled from enzymes that use NAD+ (sirtuins, PARPs, CD38) as these produce NAM as a waste product. Thus this reaction is a major source of NAD+ production in the body. De novo synthesis of NAD+ from tryptophan occurs only in the liver and kidney, overwhelmingly in the liver.
=== Tigrayan Opposition Parties === Opposition groups inside Tigray strongly rebuked the TPLF's actions. On May 11, Salsay Weyane Tigray (Sawet) issued an official statement rejecting the council's return, characterizing the assembly as a "theatrical performance" disconnected from legality and morality. The party accused the TPLF of treating the historical suffering of Tigrayans as a political tool to retain a three-decade monopoly on power. Sawet demanded an immediate halt to the political gamble and called for the creation of an all-inclusive Interim Transitional Government representing alternative civil and political stakeholders.
=== Bibliography === Hamburg Institute for Social Research, ed. (1999). The German Army and Genocide: Crimes Against War Prisoners, Jews, and Other Civilians in the East, 1939-1944. New York: New Press. ISBN 978-1-56584-525-1. Jentz, Thomas (1996). Panzertruppen Vol. 2 The Complete Guide to the Creation & Combat Employment of Germany's Tank Force 1943-1945. Atglen, PA: Schiffer Publishing. ISBN 0-7643-0080-6. Nafziger, George. "Organizational History of Miscelleanous German Named Infantry and Panzer Grenadier, Brigades, Verbands & Divisions, 1939-1945" (PDF). Combined Arms Research Library Digital Library. US Army Combined Arms Center. Retrieved 10 July 2016. Scheibert, Horst (1987). Culver, Bruce (ed.). Panzer Grenadier Division Grossdeutschland: A Pictorial History with Text & Maps. Translated by Gisele Hockenberry. Carrollton, Texas: Squadron/Signal Publications. ISBN 0-89747-061-3. Sharpe, Michael & Davis, Brian L (2001). Grossdeutschland: Guderian's Eastern Front Elite. Compendium Publishing. ISBN 0-7110-2854-0. Solarz, Jacek (2005). Division/Korps Großdeutschland 1943-1945. Vol. I and II. Warsaw: Wydawnictwo Militaria. ISBN 83-7219-237-5. Spaeter, Helmuth (1992). The History of the Panzerkorps Großdeutschland Vol I. Winnipeg, Canada: J. J. Fedorowicz Publishing. ISBN 0-921991-12-6. Spaeter, Helmuth (1995). The History of the Panzerkorps Großdeutschland Vol II. Winnipeg, Canada: J. J. Fedorowicz Publishing. ISBN 0-921991-27-4. Spaeter, Helmuth (2000). The History of the Panzerkorps Großdeutschland Vol III. Winnipeg, Canada: J. J. Fedorowicz Publishing.
Sources: en.wikipedia.org
The previous election in 2023 saw a shift towards progressive parties, with the Move Forward Party winning 151 seats followed by the Thaksin Shinawatra-aligned Pheu Thai Party. The governing coalition of conservative parties only won 15% of the seats, with the Bhumjaithai Party being the only one to increase their numbers. Move Forward initially formed an eight party coalition with Pheu Thai, Thai Sang Thai, Prachachat, Thai Liberal, New Social Power, Thai Ruam Palang and the Fair Party. The coalition had a total of 313 MPs, giving them a majority in the House of Representatives. However, under the transitory provisions of the 2017 constitution, the prime minister was to be chosen by both elected MPs and NCPO-appointed Senators. As such, Move Forward leader Pita Limjaroenrat failed to gain enough votes to become prime minister. The opportunity to form government passed to Pheu Thai who formed a coalition excluding Move Forward that included conservative parties such as Bhumjaithai, and the military-backed Palang Pracharath and United Thai Nation parties. Their candidate, Srettha Thavisin, was elected prime minister on 22 August with the support of most Senators. The 2026 election was the third election under the 2017 constitution, which was implemented under Prime Minister Prayut Chan-o-cha and the National Council for Peace and Order (NCPO) and the first after the expiration of the constitution's five-year transitory provision that gave the Senate voting rights to choose the prime minister in a joint session of parliament.
Hydrogen halides and their solutions: hydrofluoric acid (HF), hydrochloric acid (HCl), hydrobromic acid (HBr), hydroiodic acid (HI) Halogen oxoacids: hypochlorous acid (HClO), chlorous acid (HClO2), chloric acid (HClO3), perchloric acid (HClO4), and corresponding analogs for bromine and iodine Hypofluorous acid (HFO), the only known oxoacid for fluorine. Sulfuric acid (H2SO4) Fluorosulfuric acid (HSO3F) Nitric acid (HNO3) Phosphoric acid (H3PO4) Fluoroantimonic acid (HSbF6) Fluoroboric acid (HBF4) Hexafluorophosphoric acid (HPF6) Chromic acid (H2CrO4) Boric acid (H3BO3) A sulfonic acid has the general formula RS(=O)2–OH, where R is an organic radical. Methanesulfonic acid (or mesylic acid, CH3SO3H) Ethanesulfonic acid (or esylic acid, CH3CH2SO3H) Benzenesulfonic acid (or besylic acid, C6H5SO3H) p-Toluenesulfonic acid (or tosylic acid, CH3C6H4SO3H) Trifluoromethanesulfonic acid (or triflic acid, CF3SO3H) Polystyrene sulfonic acid (sulfonated polystyrene, [CH2CH(C6H4)SO3H]n)
Rubidium (37Rb) has 35 known isotopes, from 72Rb to 106Rb, with naturally occurring rubidium composed of two: stable 85Rb (72.2%) and radioactive 87Rb (27.8%). The primordial radionuclide 87Rb has a half-life of 4.97×1010 years, beta decaying to stable 87Sr. It is, as the element is, widespread on Earth as rubidium readily substitutes for potassium in all minerals. The decay of 87Rb has been used extensively in dating rocks; see rubidium–strontium dating for a more detailed discussion. Other than 87Rb, the longest-lived radioisotopes are 83Rb with a half-life of 86.2 days, 84Rb with a half-life of 32.82 days, and 86Rb with a half-life of 18.645 days. All other radioisotopes have half-lives less than a day, most less than 20 minutes. Of the isomeric states the most stable is 82mRb at 6.472 hours. The ground state of 82Rb has a much shorter half-life of 1.2575 minutes. It is used medically in some cardiac positron emission tomography scans to assess myocardial perfusion. It is synthesized through the longer-lived 82Sr, made in a cyclotron, though a generator. It may be administered as the chloride.
== History == Insulin degludec has been filed for registration in the United States. After the completion of additional cardiac safety studies requested by the US Food and Drug Administration (FDA) in February 2013, it received FDA approval in September 2015 and marketing began in January 2016.
Sources: en.wikipedia.org
=== Treatment === In vitro studies have found that several agents are effective against E. floccosum. Disease-specific topical treatments for E. floccosum-related infections are usually effective, commonly with the use of terbinafine, itraconazole, and ketoconazole.
=== Ion mobility separation === There are different types of ion mobility spectrometers and there are different types of mass spectrometers. In principle it is possible to combine every type of the former with any type of the latter. However, in the real world, different types of ion mobility are coupled with different types of mass spectrometers to achieve reasonable sensitivity. The main types of ion mobility spectrometers that have been coupled to a mass spectrometer for IM-MS applications are discussed below.
Loop diuretics are drugs that are often used for the treatment of hypertension and edema secondary to congestive heart failure, liver cirrhosis, or chronic kidney disease. Their effect, like all diuretics, is to cause the body to excrete more water in the urine. Loop diuretics are more effective than thiazide diuretics in patients with impaired kidney function. They get their name because they affect cells in a structure in the kidney called the loop of Henle.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.